Biogen (BIIB) PT Lowered to $303 at RBC Capital Ahead of District Court Rulings
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $303.00 (from $310.00) noting the risk ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
